Currently, it is not clear whether TBI-induced molecular changes (such as tau protein phosphorylation) cause irreversible damages leading to AD onset, and equally important, whether available medications can prevent or suppress AD initiation and progression. The gene discussed is MAPT; the disease is Alzheimer disease.